WFDC2 is overexpressed in ovarian cancer, particularly in endometrioid ovarian cancer (Drapkin et al., 2005), and interestingly, a current study reported WFDC2 and resectability in advanced epithelial ovarian cancer patients (Muhammad et al., 2023). Here, WFDC2 is linked to ovarian carcinoma.